Ipsen US, comprised of Ipsen Biopharmaceuticals, Inc., and Ipsen Bioscience, Inc., is driven by a passion to improve the lives of patients. A search for innovative solutions to disabling conditions is at the heart of everything we do. Ipsen team is inspired to find effective therapeutic options to treat diseases, relieve suffering, and bring value to the community. Ipsen US and its research and development team are part of an innovation-driven international specialty pharmaceutical group (the Ipsen Group), with global headquarters in Paris and US headquarters in Basking Ridge, NJ (commercial/marketing), and Massachusetts (research and development). The global company markets more than 20 drugs and employs nearly 4,600 people around the world. https://www.ipsenus.com/1-0_about.html
Sullivan & Worcester is a leading corporate law firm advising clients ranging from Fortune 500 companies to emerging businesses. With more than 185 lawyers in Boston, London, New York and Washington, D.C., the firm offers services in a wide range of areas, including corporate finance, banking, trade finance, securities and mutual funds, litigation, mergers and acquisitions, tax, real estate and REITs, private equity and venture capital, bankruptcy, environment and natural resources, climate change, renewable energy and water resources, regulatory law, and employment and benefits.
The Dassault Systèmes (DS) vision is to enable everyone—from designers to consumers and their communities—to create, share, and experience in 3D. As a world leader in 3D and Product Lifecycle Management (PLM) solutions, the company’s software and services allow businesses of any size in any industry around the globe to digitally define and simulate products, as well as the processes and resources required to manufacture, maintain, and recycle them while sustaining our environment.
EMD Millipore is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research through development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals.
The French Tech Hub (the Hub) is a growth accelerator for French High Tech Companies in the U.S. The French Tech Hub has formed an alliance with UBIFRANCE to serve IT and Life Sciences companies from all over France. The French Tech Hub is located in San Francisco and in Boston and operates as a One-Stop-Shop to provide a wide variety of services needed for American expansion: strategic coaching, marketing support, business development, domiciliation, working desk, subsidiary creation, administrative support, etc. The French Tech Hub was founded as an initiative of the Paris Region Development Agency, the French Ministry of Foreign Trade, UBIFRANCE and BPIFrance.
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Veolia Energy is a leading international provider of custom, sustainable energy services and facility operations and management solutions. From diagnostic analyses and recommendations to energy procurement and conversion, facility operations and management, and technical, financial and human resources engineering, all of our services can be assimilated into a comprehensive package.
In 2013, BioMérieux celebrated a major milestone, our 50th anniversary. Our development during these years has been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. Today, in more than 150 countries through 42 subsidiaries and a large network of distributors, bioMérieux provides diagnostic solutions that improve patient health and ensure consumer safety. We develop tests that bring high medical value for clinical decisions in the areas of infectious diseases, cardiovascular emergencies and targeted cancers. In industrial applications, we contribute to preventing contamination risks in agri-food, pharmaceutical and cosmetic products.We also bring progress to laboratories: by increasing automation and improving data management, we are helping to reinforce the efficiency of healthcare structures, increase lab productivity, and reduce healthcare costs. BioMérieux is determined to continue to play a pioneering role by innovating and designing the diagnostics of the future to address the major challenges for public health worldwide.
Established in 2009, Mérieux Développement is an evergreen fund specialized in the healthcare sector, conducting growth and venture capital investments worldwide. Mérieux Développement works alongside entrepreneurs whose products and services can bring genuine advances to the health of patients and consumers, offering them access to its industry expertise and global network. We invest in future leaders of the healthcare industry. We actively support those companies who create solutions to unmet needs and provide better access to high-value products and services through innovation. We are bringing our expertise and global network to enable outstanding entrepreneurs to disrupt and create new markets. Mérieux Développement is an affiliate of Institut Mérieux, which employs around 13,000 employees worldwide with consolidated revenues exceeding EUR 2.0 billion in 2013. Other companies owned by Institut Mérieux include bioMérieux (in vitro diagnostics), Mérieux NutriSciences (food safety and nutrition services) and Transgene (immunotherapy).
© 2017 FACC NEW ENGLAND